每經AI快(kuai)訊(xun)，萊(lai)美藥(yao)(yao)業(ye)（SZ 300006，收盤價：3.17元(yuan)）1月(yue)30日(ri)(ri)晚間發布業(ye)績預告(gao)，預計2023年(nian)歸(gui)屬于(yu)上(shang)市(shi)(shi)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)股(gu)(gu)(gu)東的(de)(de)(de)凈(jing)(jing)利(li)(li)潤(run)虧損800萬(wan)(wan)(wan)元(yuan)~1200萬(wan)(wan)(wan)元(yuan)。上(shang)年(nian)同(tong)期歸(gui)屬于(yu)上(shang)市(shi)(shi)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)股(gu)(gu)(gu)東的(de)(de)(de)凈(jing)(jing)利(li)(li)潤(run)虧損6870.91萬(wan)(wan)(wan)元(yuan)。業(ye)績變動主要原因(yin)是(shi)，控(kong)股(gu)(gu)(gu)子公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)出表。報告(gao)期內，公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)原控(kong)股(gu)(gu)(gu)子公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)四川康(kang)(kang)德(de)賽(sai)醫療(liao)科(ke)技有(you)(you)(you)限(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)以增(zeng)(zeng)資(zi)(zi)(zi)的(de)(de)(de)方式實施股(gu)(gu)(gu)權(quan)激(ji)勵，公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)和康(kang)(kang)德(de)賽(sai)其(qi)他股(gu)(gu)(gu)東放棄優先認購權(quan)。同(tong)時，康(kang)(kang)德(de)賽(sai)法(fa)定(ding)代表人暨股(gu)(gu)(gu)東丁(ding)平解(jie)除與(yu)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)關(guan)于(yu)康(kang)(kang)德(de)賽(sai)的(de)(de)(de)一致行(xing)動關(guan)系。上(shang)述事項共同(tong)導(dao)致公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)對(dui)康(kang)(kang)德(de)賽(sai)喪(sang)失控(kong)制(zhi)權(quan)從而不再納入(ru)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)合并(bing)報表范圍。企業(ye)因(yin)處置部分股(gu)(gu)(gu)權(quan)投資(zi)(zi)(zi)或其(qi)他原因(yin)喪(sang)失對(dui)原有(you)(you)(you)子公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)控(kong)制(zhi)的(de)(de)(de)，在合并(bing)財務報表中，對(dui)于(yu)剩余股(gu)(gu)(gu)權(quan)，應(ying)當按照喪(sang)失控(kong)制(zhi)權(quan)日(ri)(ri)的(de)(de)(de)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)允價值進(jin)行(xing)重(zhong)新計量。康(kang)(kang)德(de)賽(sai)出表后，公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)聘請重(zhong)慶金地房地產土(tu)地資(zi)(zi)(zi)產評(ping)(ping)估(gu)有(you)(you)(you)限(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)對(dui)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)持有(you)(you)(you)康(kang)(kang)德(de)賽(sai)約(yue)(yue)31.63%股(gu)(gu)(gu)權(quan)的(de)(de)(de)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)允價值進(jin)行(xing)了評(ping)(ping)估(gu)，并(bing)于(yu)2024年(nian)1月(yue)30日(ri)(ri)出具了《重(zhong)慶萊(lai)美藥(yao)(yao)業(ye)股(gu)(gu)(gu)份有(you)(you)(you)限(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)以財務報告(gao)為目(mu)的(de)(de)(de)所涉及的(de)(de)(de)四川康(kang)(kang)德(de)賽(sai)醫療(liao)科(ke)技有(you)(you)(you)限(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)約(yue)(yue)31.63%股(gu)(gu)(gu)權(quan)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)允價值評(ping)(ping)估(gu)項目(mu)資(zi)(zi)(zi)產評(ping)(ping)估(gu)報告(gao)》【重(zhong)金資(zi)(zi)(zi)評(ping)(ping)（2024）字第(di)0009號】，評(ping)(ping)估(gu)基準日(ri)(ri)為2023年(nian)12月(yue)31日(ri)(ri)，本次評(ping)(ping)估(gu)選用市(shi)(shi)場法(fa)，評(ping)(ping)估(gu)結果約(yue)(yue)為1.19億元(yuan)。經公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)財務部門初步核(he)算(suan)，康(kang)(kang)德(de)賽(sai)實施股(gu)(gu)(gu)權(quan)激(ji)勵與(yu)不再納入(ru)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)合并(bing)報表范圍對(dui)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)合并(bing)財務報表的(de)(de)(de)影響為：增(zeng)(zeng)加(jia)(jia)投資(zi)(zi)(zi)收益約(yue)(yue)1.09億元(yuan)，增(zeng)(zeng)加(jia)(jia)管理費用約(yue)(yue)2628.68萬(wan)(wan)(wan)元(yuan)，從而增(zeng)(zeng)加(jia)(jia)利(li)(li)潤(run)總額約(yue)(yue)8310.5萬(wan)(wan)(wan)元(yuan)，增(zeng)(zeng)加(jia)(jia)歸(gui)屬于(yu)上(shang)市(shi)(shi)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)股(gu)(gu)(gu)東的(de)(de)(de)凈(jing)(jing)利(li)(li)潤(run)約(yue)(yue)8360.12萬(wan)(wan)(wan)元(yuan)。

2022年1至12月份，萊(lai)美藥業的營(ying)業收入構成為：醫藥制造占(zhan)比85.19%，醫藥流通行業占(zhan)比10.51%，服(fu)務收入占(zhan)比2.13%。

萊美藥業的董事(shi)長是(shi)梁建生，男，41歲(sui)(sui)，學(xue)歷(li)背(bei)(bei)景為碩(shuo)士；總經(jing)理是(shi)邱戎釗，男，29歲(sui)(sui)，學(xue)歷(li)背(bei)(bei)景為本科。

截至發稿(gao)，萊美藥業市(shi)值為(wei)33億(yi)元。

道(dao)達號（daoda1997）“個(ge)股趨勢”提醒(xing)：
1. 萊美藥業近30日內北向資金持股量未發生變化；
2. 近30日內無機構對萊美藥業(ye)進行調(diao)研。

每(mei)經(jing)頭條(tiao)（nbdtoutiao）——

(記者 王曉波)

免責聲明：本文(wen)內(nei)容(rong)與數據僅供(gong)參考，不(bu)構成投(tou)資建議，使用前請(qing)核實。據此(ci)操作，風險自擔。